睿知中国医院研究地图
候选清单

武汉

湖北省肿瘤医院

Hubei Cancer Hospital

在本站收录的 61 种疾病中,这家医院列在其中 11 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

湖北省肿瘤医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma13 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma1 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma8 篇牵头论文
  4. 胃癌Stomach cancer8 篇牵头论文
  5. 肺癌Lung cancer41 篇牵头论文牵头 4 项开放试验
  6. 胰腺癌Pancreatic cancer6 篇牵头论文
  7. 乳腺癌Breast cancer45 篇牵头论文牵头 7 项开放试验
  8. 骨肉瘤Osteosarcoma1 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  10. 神经母细胞瘤Neuroblastoma0 篇牵头论文
  11. 淋巴瘤Lymphoma3 篇牵头论文

未列出的收录疾病:胶质瘤、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、冠心病、先天性心脏病、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.5%。

牵头论文
13
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 4420222023: 4420232024: 1120242025: 222025

武汉有 6 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题放疗技术诱导/同步化疗影像与人工智能
论文中的科室放疗科肿瘤内科影像/核医学科
牵头的论文13
  1. Rolling circle amplification and CRISPR/Cas14a with nanozyme for electrochemical detecting miRNA-205 in NPC-derived exosomes.2025Bioelectrochemistry (Amsterdam, Netherlands)
  2. A case report of mesalazine alleviating diarrhea in a patient with nasopharyngeal cancer after tislelizumab treatment.2025Immunotherapy免费全文
  3. Targeting the LMP1-ALIX axis in EBV+ nasopharyngeal carcinoma inhibits immunosuppressive small extracellular vesicle secretion and boosts anti-tumor immunity.2024Cancer communications (London, England)免费全文
  4. Optimizing induction chemotherapy regimens for radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.2023Cancer medicine免费全文
  5. Determination of optimum number of cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a single-center retrospective study.2023European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  6. FOXK1 regulates epithelial-mesenchymal transition and radiation sensitivity in nasopharyngeal carcinoma via the JAK/STAT3 signaling pathway.2023Genes & genomics
  7. Fluorescent aptasensor based on the MNPs-CRISPR/Cas12a-TdT for the determination of nasopharyngeal carcinoma-derived exosomes.2023Mikrochimica acta
  8. Optimal induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: an update Bayesian network meta-analysis.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  9. Notoginsenoside R1 induces oxidative stress and modulates LPS induced immune microenvironment of nasopharyngeal carcinoma.2022International immunopharmacology
  10. Pretreatment Body Mass Index (BMI) as an Independent Prognostic Factor in Nasopharyngeal Carcinoma Survival: A Systematic Review and Meta-Analysis.2022Nutrition and cancer
  11. Optimization of scan parameters to reduce acquisition time for RESOLVE-based diffusion kurtosis imaging (DKI) in nasopharyngeal carcinoma (NPC).2022The British journal of radiology免费全文
  12. Pretreatment serum vitamin level predicts severity of radiation-induced oral mucositis in patients with nasopharyngeal carcinoma.2021Head & neck
  13. Cone Beam CT (CBCT) Based Synthetic CT Generation Using Deep Learning Methods for Dose Calculation of Nasopharyngeal Carcinoma Radiotherapy.2021Technology in cancer research & treatment免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.进行中,不再招募NCT07011329牵头方2023-04 启动
  2. Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin已完成NCT02562599牵头方II期2015-08 启动
  3. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  4. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)已完成NCT03924986研究中心III期2019-03 启动
PubMed 以外找到的论文(未计入)19
  1. 1371P Nivolumab plus chemoradiotherapy sparing concurrent cisplatin in nasopharyngeal carcinoma (NPC): Social reintegration and patient-reported outcomes (PROs) in quality-of-life (QoL) and tolerability from a phase II PLATINUM trial2025Annals of Oncology论文
  2. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Research会议摘要
  3. Evaluation of Trident network against atlas and 2D U-net methods for auto-segmentation of organs at risk in nasopharyngeal carcinoma: a comparative study2025Frontiers in Physics论文
  4. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncology论文
  5. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncology会议摘要
  6. Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car2025Journal of Clinical Oncology会议摘要
  7. Validation and Development of a Refined M1 Category for Nasopharyngeal Carcinoma Based on the Ninth-Version of AJCC/UICC TNM Staging System in the Immunotherapy Era: A Multicenter Cohort Study2025International Journal of Radiation Oncology*Biology*Physics论文
  8. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Research会议摘要
  9. Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.2024Journal of Clinical Oncology会议摘要
  10. Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial2024Journal of Clinical Oncology会议摘要
  11. Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation2023Research Square预印本
  12. Refining the TNM M1 Subcategory for De Novo Metastatic Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physics论文
  13. Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation2022Research Square预印本
  14. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncology会议摘要
  15. An Interpretation of CSCO/ASCO International Guideline of Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage Ⅱ-Ⅳa Nasopharyngeal Carcinoma in 20212021DOAJ (DOAJ: Directory of Open Access Journals)论文
  16. Geometric Changes in the Parotid, Submandibular, and Thyroid Glands during Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma: A Cohort Study2021Journal of Analytical Oncology论文
  17. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost With Flattening Filter-Free Volumetric Modulated Arc Therapy for Spinal Metastases2021International Journal of Radiation Oncology*Biology*Physics论文
  18. Long Non-coding RNA PANDAR Promotes Radioresistance in Nasopharyngeal Carcinoma via SIRT1/Ku70/PI3K/Akt Pathway2021Research Square预印本
  19. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.03%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

武汉有 5 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    发布
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科
牵头的论文1
  1. Mitochondrial pathway of the lysine demethylase 5C inhibitor CPI-455 in the Eca-109 esophageal squamous cell carcinoma cell line.2021World journal of gastroenterology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
  1. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  2. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  3. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  4. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).已终止NCT04949256研究中心III期2021-07 启动
  5. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  6. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  7. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)已完成NCT04210115研究中心III期2020-02 启动
  8. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  9. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  10. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  11. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
  12. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)已完成NCT02649361研究中心II期2016-01 启动
PubMed 以外找到的论文(未计入)7
  1. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncology论文
  2. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Research会议摘要
  3. High versus standard radiation dose of definitive chemoradiotherapy combined with immunotherapy for inoperable esophageal squamous cell carcinoma: A multicenter propensity score matching analysis.2024Journal of Clinical Oncology会议摘要
  4. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncology会议摘要
  5. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncology会议摘要
  6. Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncology会议摘要
  7. Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.05%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 0020222023: 1120232024: 1120242025: 332025

武汉有 6 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    发布
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  2. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    发布
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物局部治疗(消融、TACE、HAIC)复发与预后
论文中的科室肿瘤内科放疗科普外/肝胆胰外科

这些论文过半是实验室或动物研究。

牵头的论文8
  1. Highly Sensitive Digital and Analog Immunoassay Based on Submicron Magnetic Beads and Fluorescent Microspheres.2025Analytical chemistry
  2. A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTEFAP5/CD3, CAR-T cells, and immunotoxins in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  3. Causal relationships among gut microbiota, plasma metabolites, and hepatocellular carcinoma: A mediation Mendelian randomization study.2025Medicine免费全文
  4. A study on combination of non-ablative local RFA with PD-1 and angiogenesis blocking to prolong survival through improvement of immune microenvironment in advanced Hepatocellular Carcinoma.2024International immunopharmacology
  5. [Apatinib Suppressed Macrophage-Mediated Malignant Behavior of Hepatocellular Carcinoma Cells via Modulation of VEGFR2/STAT3/PD-L1 Signaling].2023Molekuliarnaia biologiia
  6. GAS6-AS2 Promotes Hepatocellular Carcinoma via miR-3619-5p/ARL2 Axis Under Insufficient Radiofrequency Ablation Condition.2021Cancer biotherapy & radiopharmaceuticals
  7. miR-143-3p inhibits proliferation and invasion of hepatocellular carcinoma cells by regulating its target gene FGF1.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  8. HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis.2021Journal of immunology research免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  2. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  3. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)已终止NCT06487559研究中心I期2024-09 启动
  4. A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC已撤回NCT05212922研究中心II期2023-06 启动
  5. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  6. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  7. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  8. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  9. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  10. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)已完成NCT03867084研究中心III期2019-05 启动
  11. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  12. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动
  13. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  14. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.08%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 2220232024: 2220242025: 332025

武汉有 5 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 7

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    发布
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
    分期
    II/III期
    开始
    2026-05
    发布
    登记号
    NCT07392892

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、广州、成都、武汉

  3. 正在招募
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    分期
    III期
    开始
    2025-02
    发布
    登记号
    NCT06731478

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川

  4. 正在招募
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    分期
    III期
    开始
    2025-05
    发布
    登记号
    NCT06901531

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、成都、杭州、武汉、石家庄、福州、西宁、郑州

  5. 正在招募
    A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
    分期
    I/II期
    开始
    2025-08
    发布
    登记号
    NCT07070232

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心天津、杭州、武汉、重庆

  6. 正在招募
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    分期
    II/III期
    开始
    2024-02
    发布
    登记号
    NCT06221748

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、厦门、哈尔滨、徐州、成都、昆明、武汉、济南、郑州、长沙、青岛

  7. 正在招募
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    分期
    I期
    开始
    2021-06
    发布
    登记号
    NCT04900818

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题化疗与综合治疗免疫与靶向药物腹膜转移与晚期
论文中的科室肿瘤内科影像/核医学科
牵头的论文8
  1. Overall survival according to time-of-day of combined immuno-chemotherapy for advanced gastric cancer: a propensity score-matched analysis.2025Frontiers in immunology免费全文
  2. BE screen reveals METTL3 S2 dephosphorylation sensitizes gastric cancer cells to oxaliplatin by interfering METTL3-eIF3H interaction.2025Science advances免费全文
  3. A Mitochondrion-Targeted NIR-II Modulator for Synergistic Ferroptosis-Immunotherapy.2025Small (Weinheim an der Bergstrasse, Germany)
  4. Efficacy of sintilimab combined with neoadjuvant chemotherapy and trastuzumab in conversional treatment of locally advanced HER2-positive gastric cancer: case analysis and literature review.2024Journal of cancer research and clinical oncology免费全文
  5. Short-Term Safety Evaluation of Albumin-Bound Paclitaxel in Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer.2024Journal of gastrointestinal cancer
  6. The organic arsenical-derived thioredoxin and glutathione system inhibitor ACZ2 induces apoptosis and autophagy in gastric cancer via ROS-dependent ER stress.2023Biochemical pharmacology
  7. A radiomics nomogram analysis based on CT images and clinical features for preoperative Lauren classification in gastric cancer.2023Japanese journal of radiology
  8. The combination of body composition conditions and systemic inflammatory markers has prognostic value for patients with gastric cancer treated with adjuvant chemoradiotherapy.2022Nutrition (Burbank, Los Angeles County, Calif.)
中文论文(未计入)1
  1. AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer.2023Journal of Zhejiang University. Science. B免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)26
  1. Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer正在招募NCT07392892研究中心II/III期2026-05 启动
  2. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  3. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer正在招募NCT06731478研究中心III期2025-02 启动
  4. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer正在招募NCT06901531研究中心III期2025-05 启动
  5. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors正在招募NCT07070232研究中心I/II期2025-08 启动
  6. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy正在招募NCT06221748研究中心II/III期2024-02 启动
  7. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors正在招募NCT04900818研究中心I期2021-06 启动
  8. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  9. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma已终止NCT06206278研究中心II期2023-10 启动
  10. Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia已完成NCT05606094研究中心2023-03 启动
  11. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  12. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer已终止NCT05149807研究中心II/III期2022-01 启动
  13. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  14. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  15. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.已终止NCT05188209研究中心II期2021-12 启动
  16. A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)已终止NCT04933227研究中心II期2021-08 启动
  17. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  18. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations状态不明NCT05019794研究中心II期2020-05 启动
  19. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  20. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  21. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment已终止NCT04178460研究中心I期2020-02 启动
  22. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  23. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  24. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  25. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension已撤回NCT04859582研究中心III期2018-11 启动
  26. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 41 篇,占 0.2%。

牵头论文
41
2021–2025 年
牵头试验
7
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
31
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 4420222023: 4420232024: 121220242025: 14142025

武汉有 5 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 35

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
    分期
    不分期
    开始
    2024-02
    发布
    登记号
    NCT06020430

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:湖北省肿瘤医院武汉

  2. 正在招募
    Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients
    分期
    II期
    开始
    2024-02
    发布
    登记号
    NCT06032052

    年龄 65 岁 至 未注明(登记的条件)

    牵头:湖北省肿瘤医院武汉

  3. 正在招募
    Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
    分期
    不分期
    开始
    2024-03
    发布
    登记号
    NCT06037733

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:湖北省肿瘤医院武汉

  4. 即将招募
    Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC
    分期
    II期
    开始
    2026-09
    发布
    登记号
    NCT07807722

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:湖北省肿瘤医院武汉

  5. 正在招募
    ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
    分期
    II期
    开始
    2026-03
    发布
    登记号
    NCT06951646

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中南大学湘雅二医院;另有 12 家列出的医院为研究中心南宁、南昌、太原、新乡、武汉、沈阳、重庆、长沙

  6. 正在招募
    A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
    分期
    II/III期
    开始
    2026-01
    发布
    登记号
    NCT07063745

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、北京、南宁、南昌、厦门、哈尔滨、广州、成都、杭州、武汉、沈阳、福州、长沙

  7. 正在招募
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    分期
    III期
    开始
    2026-01
    发布
    登记号
    NCT07222566

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、台州、合肥、太原、广州、成都、扬州、新乡、杭州、武汉、江门、洛阳、济南、温州、福州、襄阳、郑州、重庆、长春、长沙

  8. 正在招募
    A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
    分期
    II期
    开始
    2026-02
    发布
    登记号
    NCT07253142

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、南宁、合肥、哈尔滨、广州、徐州、新乡、武汉、福州

  9. 正在招募
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    分期
    III期
    开始
    2026-04
    发布
    登记号
    NCT07416474

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 66 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、桂林、武汉、江门、沈阳、洛阳、济南、深圳、温州、烟台、珠海、石家庄、福州、苏州、襄阳、郑州、重庆、银川、长春、长沙、青岛

  10. 正在招募
    A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
    分期
    III期
    开始
    2026-06
    发布
    登记号
    NCT07554339

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 26 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、厦门、台州、合肥、太原、广州、成都、杭州、桂林、武汉、济南、温州、石家庄、福州、重庆、长沙

  11. 正在招募
    A Study of DS-3939a in Participants With Solid Tumors
    分期
    I/II期
    开始
    2026-10
    发布
    登记号
    NCT07739966

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、台州、哈尔滨、天津、广州、杭州、武汉、济南、郑州、长春、长沙

  12. 正在招募
    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
    分期
    III期
    开始
    2025-07
    发布
    登记号
    NCT06758401

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、台州、合肥、哈尔滨、天津、常州、广州、徐州、成都、杭州、武汉、洛阳、济南、温州、福州、西安、郑州、长沙

  13. 正在招募
    A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
    分期
    III期
    开始
    2025-10
    发布
    登记号
    NCT06793215

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南昌、南通、合肥、哈尔滨、广州、成都、昆明、杭州、武汉、汕头、济南、蚌埠、长沙

  14. 正在招募
    Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
    分期
    未注明
    开始
    2025-02
    发布
    登记号
    NCT06809764

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 30 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、厦门、合肥、广州、杭州、武汉、沈阳、济南、深圳、石家庄、福州、郑州、青岛

  15. 正在招募
    A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
    分期
    I期
    开始
    2025-02
    发布
    登记号
    NCT06839105

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南昌、哈尔滨、广州、昆明、杭州、武汉、沈阳、洛阳、福州、长春、长沙

  16. 正在招募
    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
    分期
    III期
    开始
    2025-03
    发布
    登记号
    NCT06890598

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、佛山、北京、南宁、台州、哈尔滨、天津、安阳、广州、成都、杭州、武汉、汕头、洛阳、济南、深圳、苏州、西安、重庆、长沙

  17. 正在招募
    Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
    分期
    III期
    开始
    2025-10
    发布
    登记号
    NCT06899126

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、北京、南京、南昌、合肥、哈尔滨、天津、太原、广州、成都、杭州、武汉、沈阳、济南、襄阳、郑州、重庆、长春、长沙

  18. 正在招募
    A Study of SKB518 in Patients With Lung Cancer
    分期
    II期
    开始
    2025-08
    发布
    登记号
    NCT07019675

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、南宁、南昌、台州、天津、太原、昆明、杭州、武汉、济南、深圳、襄阳、郑州、长沙

  19. 正在招募
    A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
    分期
    I/II期
    开始
    2025-09
    发布
    登记号
    NCT07111520

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、南昌、合肥、天津、广州、徐州、成都、扬州、新乡、武汉、济南、石家庄、福州、苏州、襄阳、重庆、长春、青岛

  20. 正在招募
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    分期
    III期
    开始
    2025-12
    发布
    登记号
    NCT07182682

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 47 家列出的医院为研究中心上海、北京、南京、南宁、台州、合肥、哈尔滨、天津、太原、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、福州、西安、郑州、长春、长沙

  21. 正在招募
    A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
    分期
    III期
    开始
    2025-10
    发布
    登记号
    NCT07190248

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、台州、合肥、太原、广州、成都、杭州、武汉、福州、西安、郑州、重庆、长沙

  22. 正在招募
    A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
    分期
    III期
    开始
    2025-11
    发布
    登记号
    NCT07218146

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、广州、成都、杭州、武汉、济南、石家庄、福州、西安、郑州、长春、长沙

  23. 正在招募
    A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT06203210

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南昌、哈尔滨、天津、成都、杭州、武汉、沈阳、济南、烟台、襄阳、郑州、重庆、长沙

  24. 正在招募
    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
    分期
    III期
    开始
    2024-04
    发布
    登记号
    NCT06312137

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南昌、台州、广州、成都、杭州、武汉、济南、福州、苏州、西安、郑州、长春、长沙

  25. 正在招募
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT06345729

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、无锡、杭州、武汉、济南、温州、福州、苏州、西安、郑州、重庆、长沙

  26. 正在招募
    JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
    分期
    III期
    开始
    2024-08
    发布
    登记号
    NCT06416410

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、临沂、北京、南京、南宁、台州、哈尔滨、天津、太原、广州、成都、无锡、杭州、武汉、沈阳、济南、深圳、福州、西安、郑州、长沙、青岛

  27. 正在招募
    A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    分期
    III期
    开始
    2024-08
    发布
    登记号
    NCT06452277

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、临沂、北京、南京、厦门、台州、哈尔滨、广州、成都、杭州、武汉、济南、福州、长春、长沙

  28. 正在招募
    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
    分期
    III期
    开始
    2023-11
    发布
    登记号
    NCT06095583

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、北京、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、成都、杭州、武汉、沈阳、济南、深圳、郑州、重庆、银川、长春、长沙、青岛

  29. 正在招募
    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
    分期
    III期
    开始
    2023-12
    发布
    登记号
    NCT06170788

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南昌、厦门、台州、合肥、哈尔滨、广州、徐州、成都、无锡、杭州、武汉、济南、湛江、石家庄、福州、襄阳、郑州、长沙

  30. 正在招募
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    分期
    III期
    开始
    2022-03
    发布
    登记号
    NCT04928846

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南宁、南昌、南通、厦门、台州、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、昆明、杭州、武汉、汕头、沈阳、济南、湛江、石家庄、福州、西安、郑州、重庆、长春、长沙

  31. 正在招募
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    分期
    I/II期
    开始
    2021-09
    发布
    登记号
    NCT04930432

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 56 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、南通、厦门、台州、合肥、哈尔滨、大连、天津、太原、广州、徐州、成都、昆明、杭州、武汉、汕头、沈阳、济南、深圳、温州、潍坊、烟台、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长春、长沙、青岛

  32. 正在招募
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
    分期
    II期
    开始
    2020-09
    发布
    登记号
    NCT04557449

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、杭州、武汉、西安、郑州

  33. 正在招募
    Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
    分期
    I/II期
    开始
    2019-07
    发布
    登记号
    NCT04270591

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、济南、石家庄、郑州、长春、长沙

  34. 即将招募
    A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    分期
    II/III期
    开始
    2026-11
    发布
    登记号
    NCT07865910

    年龄 18 天 至 75 天(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心北京、南宁、安阳、广州、徐州、武汉、济南、石家庄、遵义、郑州、重庆、青岛

  35. 即将招募
    A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
    分期
    III期
    开始
    2023-11
    发布
    登记号
    NCT05990127

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、合肥、哈尔滨、天津、太原、广州、徐州、成都、新乡、昆明、杭州、武汉、沈阳、洛阳、济南、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、银川、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科放疗科病理/检验科影像/核医学科
牵头的论文41
  1. FAM107A Inhibits the Growth, Invasion and Aerobic Glycolysis of LUAD Cells by Regulating CRYAB/PI3K/AKT.2026Biochemical genetics
  2. Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer with Primary Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospecti2026Oncology
  3. Intraductal chemotherapy for triple-negative breast cancer: a pathway to minimally invasive clinical treatment.2025BMC cancer免费全文
  4. Anlotinib as a Tailored Treatment for Extensive-Stage Small Cell Lung Cancer with Stable Disease after Two Cycles of First Chemotherapy Plus Immunotherapy: A Retrospective Study.2025Cancer biotherapy & radiopharmaceuticals
  5. Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospect2025Cancer control : journal of the Moffitt Cancer Center免费全文
  6. Tumor-Associated Macrophages: Key Players in the Non-Small Cell Lung Cancer Tumor Microenvironment.2025Cancer medicine免费全文
  7. Efficacy and Safety of PD-1/L1 Inhibitors Combined with Anlotinib versus PD-1/L1 Inhibitors Combined with Bevacizumab in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients: A Comparative Cohort Study.2025Current cancer drug targets
  8. Salidroside Enhances the Sensitivity of Lung Cancer Cells to Paclitaxel by Regulating the Wnt/β-catenin Signaling Pathway.2025Current medical science
  9. Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  10. Case Report: Prognostic evaluation of immunotherapy in two patients with SMARCA4-UT using TCR as a new marker.2025Frontiers in immunology免费全文
  11. Research progress on treatment-associated pneumonitis in lung cancer patients undergoing radiotherapy and immunotherapy.2025Future oncology (London, England)免费全文
  12. Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer.2025International journal of biological sciences免费全文
  13. Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy.2025Journal of chemotherapy (Florence, Italy)
  14. Development of a Cellular Senescence-Related Risk Model as a Prognostic Biomarker and Immunotherapy Response in Lung Squamous Cell Carcinoma.2025Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  15. Temozolomide and anlotinib as second-line therapy for non-small cell lung cancer patients with brain metastases: a retrospective cohort study.2025Neoplasma
  16. Advances in molecular pathology and therapy of non-small cell lung cancer.2025Signal transduction and targeted therapy免费全文
  17. Evaluation of Radiotherapy Efficacy and Prognostic Analysis for Solid and Cystic Brain Metastases.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  18. The Efficacy and Safety of Albumin-Bound Paclitaxel Combined With Anlotinib and PD-1/L1 Inhibitors For Treating Patients With Extensive-Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study.2024Cancer medicine免费全文
  19. Single-drug Chemotherapy Plus Immunotherapy as First-line Treatment for Stage Ⅳ Non-small Cell Lung Cancer Elderly Patients: A Phase II Clinical Trial UNICORN Study.2024Clinical lung cancer
  20. Unraveling the obesity paradox in small cell lung cancer immunotherapy: unveiling prognostic insights through body composition analysis.2024Frontiers in immunology免费全文
  21. Targeting CENP-E augments immunotherapy in non-small cell lung cancer via stabilizing PD-L1.2024International immunopharmacology
  22. The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort.2024Journal of cancer research and clinical oncology免费全文
  23. Impact of Baduanjin Qigong Exercise on Fatigue in Patients with Lung Cancer: A Randomized Controlled Trial.2024Journal of palliative medicineRCT
  24. A fluorescence-based lateral flow immunoassay using AIEgen-encapsulated nanoparticles to rapidly and sensitively detect pro-gastrin-releasing peptide.2024Mikrochimica acta
  25. Albumin bound-paclitaxel combined with anlotinib and immunotherapy in the second-line treatment of ES-SCLC: a retrospective cohort study.2024Neoplasma
  26. Integration of dosimetric parameters, clinical factors, and radiomics to predict symptomatic radiation pneumonitis in lung cancer patients undergoing combined immunotherapy and radiotherapy.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  27. Dosimetric predictors of radiation pneumonitis in patients with prior immunotherapy exposure: A multi-institutional analysis.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  28. Oxymatrine induces apoptosis in non-small cell lung cancer cells by downregulating TRIM46.2024Toxicon : official journal of the International Society on Toxinology
  29. Manganese Dioxide/Gold-based Active Tumor Targeting Nanoprobes for Enhancing Photodynamic and Low-Temperature-Photothermal Combination Therapy in Lung Cancer.2023ACS applied materials & interfaces
  30. Comparative clinical outcomes and predictive biomarkers of sintilimab combinations vs. single therapy in cancer: a systematic review and meta-analysis of randomized controlled trials.2023European review for medical and pharmacological sciences
  31. Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review.2023Frontiers in immunology免费全文
  32. Boosting the abscopal effect with chemoradiotherapy/immunotherapy combination in metastatic cervical cancer: a case report.2023Immunotherapy
  33. Long-term survival in a patient with advanced lung adenocarcinoma harboring synchronous EGFR exon 18 G719A and BRAF V600E mutations and treated with afatinib: a case report.2022Anti-cancer drugs
  34. CHRAC1 promotes human lung cancer growth through regulating YAP transcriptional activity.2022Carcinogenesis
  35. Peripheral Polyfunctional PD1+ CD8+ T cells demonstrated strong immune protection in non-small cell lung cancer.2022European journal of immunology免费全文
  36. A pilot study of function-based radiation therapy planning for lung cancer using hyperpolarized xenon-129 ventilation MRI.2022Journal of applied clinical medical physics免费全文
  37. MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING.2021Cancer discovery
  38. Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non-small-cell Lung Cancer: Study Protocol for an Open-label Randomized Controlled Trial.2021Clinical lung cancer
  39. Hollow PtCo alloy nanospheres as a high-Z and oxygen generating nanozyme for radiotherapy enhancement in non-small cell lung cancer.2021Journal of materials chemistry. B
  40. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.2021The international journal of biochemistry & cell biology
  41. Clinical characteristics and risk factors for in-hospital mortality of lung cancer patients with COVID-19: A multicenter, retrospective, cohort study.2021Thoracic cancer免费全文
中文论文(未计入)3
  1. [Study on dyeing effect of elastic fiber under different incubation conditions of Victoria Blue dye solution].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Survival analysis of malignant tumors in cancer registration areas of Hubei province in China, 2013 to 2015].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  3. [Impact of the depth of remission by induction chemotherapy on the prognosis of limited stage small cell lung cancer].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)93
  1. Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC即将招募NCT07807722牵头方II期2026-09 启动
  2. Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy正在招募NCT06037733牵头方不分期2024-03 启动
  3. Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients正在招募NCT06032052牵头方II期2024-02 启动
  4. Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy正在招募NCT06020430牵头方不分期2024-02 启动
  5. Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors已完成NCT05801133牵头方II期2023-03 启动
  6. Impact of Baduanjin Qigong Exercise on Fatigue in Patients With NSCLC Undergoing Adjuvant Chemotherapy状态不明NCT05159167牵头方不分期2021-12 启动
  7. Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC已完成NCT05021328牵头方I期2021-10 启动
  8. A Study of DS-3939a in Participants With Solid Tumors正在招募NCT07739966研究中心I/II期2026-10 启动
  9. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion正在招募NCT07063745研究中心II/III期2026-01 启动
  10. ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)正在招募NCT06951646研究中心II期2026-03 启动
  11. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer正在招募NCT07222566研究中心III期2026-01 启动
  12. A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer即将招募NCT07865910研究中心II/III期2026-11 启动
  13. A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer正在招募NCT07253142研究中心II期2026-02 启动
  14. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)正在招募NCT07416474研究中心III期2026-04 启动
  15. A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)正在招募NCT07554339研究中心III期2026-06 启动
  16. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.正在招募NCT06758401研究中心III期2025-07 启动
  17. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery正在招募NCT07182682研究中心III期2025-12 启动
  18. A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies正在招募NCT06839105研究中心I期2025-02 启动
  19. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer正在招募NCT06793215研究中心III期2025-10 启动
  20. A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)正在招募NCT07218146研究中心III期2025-11 启动
  21. Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)正在招募NCT06809764研究中心2025-02 启动
  22. A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)正在招募NCT07190248研究中心III期2025-10 启动
  23. Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer正在招募NCT06899126研究中心III期2025-10 启动
  24. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer正在招募NCT06890598研究中心III期2025-03 启动
  25. A Study of SKB518 in Patients With Lung Cancer正在招募NCT07019675研究中心II期2025-08 启动
  26. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)正在招募NCT07111520研究中心I/II期2025-09 启动
  27. A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)正在招募NCT06452277研究中心III期2024-08 启动
  28. A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer正在招募NCT06203210研究中心III期2024-05 启动
  29. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)正在招募NCT06345729研究中心III期2024-05 启动
  30. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)正在招募NCT06312137研究中心III期2024-04 启动
  31. JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation正在招募NCT06416410研究中心III期2024-08 启动
  32. A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer即将招募NCT05990127研究中心III期2023-11 启动
  33. Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)正在招募NCT06095583研究中心III期2023-11 启动
  34. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)正在招募NCT06170788研究中心III期2023-12 启动
  35. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)正在招募NCT04928846研究中心III期2022-03 启动
  36. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors正在招募NCT04930432研究中心I/II期2021-09 启动
  37. Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors正在招募NCT04557449研究中心II期2020-09 启动
  38. Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer正在招募NCT04270591研究中心I/II期2019-07 启动
  39. A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors进行中,不再招募NCT07160335研究中心I期2025-09 启动
  40. A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer进行中,不再招募NCT07005336研究中心II期2025-01 启动
  41. Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)进行中,不再招募NCT06117774研究中心III期2024-02 启动
  42. Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab进行中,不再招募NCT06211036研究中心III期2024-06 启动
  43. A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer进行中,不再招募NCT06711900研究中心III期2024-10 启动
  44. Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)进行中,不再招募NCT06305754研究中心III期2024-06 启动
  45. A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer进行中,不再招募NCT06448312研究中心III期2024-06 启动
  46. Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer已完成NCT05577702研究中心II期2023-03 启动
  47. A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery已完成NCT05872763研究中心2023-08 启动
  48. A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer已完成NCT05635708研究中心II期2023-02 启动
  49. Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)进行中,不再招募NCT05555732研究中心III期2023-01 启动
  50. A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC已撤回NCT05212922研究中心II期2023-06 启动
  51. A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)进行中,不再招募NCT05816252研究中心II期2023-04 启动
  52. ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors进行中,不再招募NCT05671510研究中心III期2023-06 启动
  53. A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors状态不明NCT06143735研究中心II期2023-12 启动
  54. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)进行中,不再招募NCT06074588研究中心III期2023-11 启动
  55. Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)进行中,不再招募NCT05609968研究中心III期2023-02 启动
  56. Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.状态不明NCT05922345研究中心III期2023-06 启动
  57. A Study of AL8326 in Non-Small Cell Lung Cancer进行中,不再招募NCT06794957研究中心I期2022-05 启动
  58. Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations进行中,不再招募NCT05215340研究中心III期2022-03 启动
  59. Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)已完成NCT05298423研究中心III期2022-05 启动
  60. A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer进行中,不再招募NCT05353257研究中心III期2022-05 启动
  61. Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)进行中,不再招募NCT05224141研究中心III期2022-03 启动
  62. AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer已终止NCT04993391研究中心I/II期2021-07 启动
  63. Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer已终止NCT04921358研究中心III期2021-07 启动
  64. A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer已终止NCT04746924研究中心III期2021-05 启动
  65. Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)进行中,不再招募NCT05712902研究中心II期2021-07 启动
  66. A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.已终止NCT04619433研究中心III期2021-02 启动
  67. Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)进行中,不再招募NCT04656652研究中心III期2020-12 启动
  68. Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)进行中,不再招募NCT04380636研究中心III期2020-07 启动
  69. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  70. Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy已完成NCT04447118研究中心III期2020-09 启动
  71. A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)状态不明NCT04325763研究中心III期2020-05 启动
  72. IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer已完成NCT04434482研究中心I/II期2020-08 启动
  73. A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer已完成NCT04619797研究中心II/III期2020-12 启动
  74. TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations已完成NCT04129502研究中心III期2020-01 启动
  75. Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)进行中,不再招募NCT04624204研究中心III期2020-12 启动
  76. A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)已完成NCT04194203研究中心III期2020-04 启动
  77. Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)进行中,不再招募NCT04379635研究中心III期2020-05 启动
  78. Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)已完成NCT03829319研究中心III期2019-03 启动
  79. A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC状态不明NCT04033354研究中心III期2019-08 启动
  80. A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer状态不明NCT04641754研究中心II期2019-03 启动
  81. Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study已完成NCT04716933研究中心III期2019-11 启动
  82. A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)已完成NCT03940703研究中心II期2019-09 启动
  83. Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)进行中,不再招募NCT03974022研究中心I/II期2019-07 启动
  84. A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC状态不明NCT03668496研究中心III期2018-11 启动
  85. A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer已完成NCT03594747研究中心III期2018-07 启动
  86. A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer已完成NCT03663205研究中心III期2018-07 启动
  87. A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)已终止NCT03033511研究中心III期2017-02 启动
  88. Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)已完成NCT03358875研究中心III期2017-11 启动
  89. A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients状态不明NCT04237805研究中心I/II期2016-11 启动
  90. eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients进行中,不再招募NCT02767804研究中心III期2016-06 启动
  91. A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer已完成NCT02716116研究中心I/II期2016-06 启动
  92. Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).已完成NCT02831959研究中心III期2016-07 启动
  93. BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)已完成NCT01121393研究中心III期2010-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胰腺癌

Pancreatic cancer

2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.1%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 2220232024: 2220242025: 112025

武汉有 5 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
    分期
    II/III期
    开始
    2024-05
    发布
    登记号
    NCT06361888

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、合肥、哈尔滨、天津、广州、成都、昆明、杭州、武汉、沈阳、济南、海口、深圳、温州、福州、苏州、西安、郑州、重庆、长沙

  2. 正在招募
    A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
    分期
    II期
    开始
    2023-10
    发布
    登记号
    NCT06008288

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、济南、福州、西安、郑州、长沙、青岛

  3. 正在招募
    Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
    分期
    I/II期
    开始
    2023-12
    发布
    登记号
    NCT06799637

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、北京、合肥、广州、成都、昆明、杭州、武汉、洛阳、福州、贵阳、重庆、长沙

  4. 正在招募
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    分期
    I期
    开始
    2021-06
    发布
    登记号
    NCT04900818

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室普外/肝胆胰外科放疗科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文6
  1. Harnessing the power of cancer-associated fibroblasts to revolutionize pancreatic cancer treatment.2025Cancer biology & medicine免费全文
  2. Online adaptive radiotherapy in stereotactic body radiotherapy for pancreatic cancer patients.2024Scientific reports免费全文
  3. NNT-AS1 in CAFs-derived exosomes promotes progression and glucose metabolism through miR-889-3p/HIF-1α in pancreatic adenocarcinoma.2024Scientific reports免费全文
  4. 25-hydroxyvitamin D concentration is positively associated with overall survival in advanced pancreatic cancer: A systematic review and meta-analysis.2023Nutrition research (New York, N.Y.)
  5. The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.2023World journal of surgical oncology免费全文
  6. A novel circ_0099999/miR-330-5p/FSCN1 ceRNA crosstalk in pancreatic cancer.2021Autoimmunity
中文论文(未计入)1
  1. [Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells: report of two cases].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer正在招募NCT06361888研究中心II/III期2024-05 启动
  2. A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.正在招募NCT06008288研究中心II期2023-10 启动
  3. Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments正在招募NCT06799637研究中心I/II期2023-12 启动
  4. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors正在招募NCT04900818研究中心I期2021-06 启动
  5. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  6. A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy已终止NCT04300114研究中心III期2020-08 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 45 篇,占 0.3%。

牵头论文
45
2021–2025 年
牵头试验
8
任何状态,ClinicalTrials.gov
牵头的开放试验
7
正在或即将招募
作为研究中心的开放试验
18
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 4420222023: 6620232024: 101020242025: 17172025

武汉有 7 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 25

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study on Combined Low-pass Whole-genome and Methylome Testing of Bloody Nipple Discharge Specimens for Benign-Malignant Differentiation.
    分期
    未注明
    开始
    2025-12
    发布
    登记号
    NCT07250204

    年龄 18 岁 至 未注明(登记的条件)

    牵头:湖北省肿瘤医院武汉

  2. 正在招募
    DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes
    分期
    未注明
    开始
    2025-12
    发布
    登记号
    NCT07263347

    年龄 18 岁 至 70 岁;仅女性(登记的条件)

    牵头:湖北省肿瘤医院武汉

  3. 正在招募
    Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib
    分期
    未注明
    开始
    2025-12
    发布
    登记号
    NCT07264985

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:湖北省肿瘤医院武汉

  4. 正在招募
    Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea
    分期
    未注明
    开始
    2025-12
    发布
    登记号
    NCT07264998

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:湖北省肿瘤医院武汉

  5. 正在招募
    SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
    分期
    II期
    开始
    2024-11
    发布
    登记号
    NCT06401005

    年龄 18 岁 至 未注明;仅女性(登记的条件)

    牵头:湖北省肿瘤医院武汉

  6. 正在招募
    SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer
    分期
    II期
    开始
    2024-11
    发布
    登记号
    NCT06402435

    年龄 18 岁 至 未注明;仅女性(登记的条件)

    牵头:湖北省肿瘤医院武汉

  7. 邀请入组
    Investigating the Effects of Different Incision Types on Aesthetic Outcomes and Incision-related Complications After Breast Reconstruction Surgery
    分期
    未注明
    开始
    2023-07
    发布
    登记号
    NCT06258863

    年龄 18 岁 至 未注明;仅女性(登记的条件)

    牵头:湖北省肿瘤医院武汉

  8. 正在招募
    Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
    分期
    未注明
    开始
    2026-05
    发布
    登记号
    NCT06993506

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院肿瘤医院;另有 12 家列出的医院为研究中心上海、北京、厦门、合肥、武汉、烟台、石家庄、福州、郑州、长春

  9. 正在招募
    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
    分期
    未注明
    开始
    2026-01
    发布
    登记号
    NCT07347600

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、扬州、武汉、沈阳、济南、海口、潍坊、石家庄、西安、贵阳、郑州、重庆、长春

  10. 正在招募
    RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
    分期
    II/III期
    开始
    2026-05
    发布
    登记号
    NCT07413939

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、合肥、天津、广州、成都、昆明、杭州、武汉、汕头、济南、福州、蚌埠、长沙

  11. 正在招募
    Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain
    分期
    不分期
    开始
    2026-04
    发布
    登记号
    NCT07490938

    年龄 18 岁 至 75 岁;仅女性(登记的条件)

    牵头:天津中医药大学第一附属医院;另有 3 家列出的医院为研究中心天津、武汉、西宁

  12. 正在招募
    BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
    分期
    III期
    开始
    2026-05
    发布
    登记号
    NCT07492641

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、哈尔滨、天津、广州、成都、昆明、杭州、武汉、汕头、海口、温州、潍坊、石家庄、福州、蚌埠、西安、郑州、重庆、长沙

  13. 正在招募
    A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
    分期
    II期
    开始
    2026-10
    发布
    登记号
    NCT07876557

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心兰州、北京、南京、南昌、哈尔滨、太原、广州、成都、武汉、沈阳、济南、潍坊、石家庄、福州、贵阳、郑州、银川、长春、长沙、青岛

  14. 正在招募
    A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
    分期
    II/III期
    开始
    2025-09
    发布
    登记号
    NCT06926868

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 24 家列出的医院为研究中心兰州、北京、南宁、南昌、合肥、天津、太原、安阳、广州、成都、昆明、杭州、武汉、沈阳、济南、福州、襄阳、郑州、青岛

  15. 正在招募
    JS207 Combination Therapy in Triple-negative Breast Cancer
    分期
    II期
    开始
    2025-09
    发布
    登记号
    NCT07045311

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心乌鲁木齐、北京、南京、合肥、哈尔滨、大连、杭州、武汉、沈阳、石家庄、西安、郑州、长春、青岛

  16. 正在招募
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
    分期
    III期
    开始
    2025-08
    发布
    登记号
    NCT07062965

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、大连、广州、杭州、武汉、济南、温州、石家庄、福州、西安、长春、长沙

  17. 正在招募
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    分期
    III期
    开始
    2025-01
    发布
    登记号
    NCT07673029

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 51 家列出的医院为研究中心上海、临沂、北京、南宁、南昌、合肥、哈尔滨、大连、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、梅州、武汉、汕头、沈阳、泉州、洛阳、济南、潍坊、烟台、石家庄、福州、蚌埠、西安、贵阳、郑州、重庆、长春、长沙、青岛

  18. 正在招募
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
    分期
    III期
    开始
    2023-06
    发布
    登记号
    NCT05646862

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心南京、南昌、天津、广州、成都、杭州、武汉、济南、重庆、长春

  19. 正在招募
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    分期
    III期
    开始
    2023-10
    发布
    登记号
    NCT05696626

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 57 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、大连、天津、宁波、安阳、广州、徐州、成都、昆明、杭州、梅州、武汉、沈阳、泸州、洛阳、海口、深圳、温州、石家庄、福州、蚌埠、襄阳、西安、郑州、重庆、长春、长沙、青岛

  20. 正在招募
    A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
    分期
    III期
    开始
    2023-09
    发布
    登记号
    NCT05894239

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南宁、南昌、天津、成都、杭州、武汉、洛阳、济南、石家庄、福州、长春

  21. 正在招募
    A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
    分期
    I/II期
    开始
    2023-09
    发布
    登记号
    NCT06064812

    年龄 18 岁 至 未注明;仅女性(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、南京、南宁、合肥、天津、广州、成都、杭州、武汉、沈阳、洛阳、济南、郑州、长春

  22. 正在招募
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    分期
    II期
    开始
    2023-12
    发布
    登记号
    NCT06107686

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南宁、南昌、台州、合肥、哈尔滨、太原、广州、徐州、成都、杭州、桂林、梅州、武汉、汕头、沈阳、济南、潍坊、苏州、襄阳、西安、郑州、重庆、长春、长沙、青岛

  23. 正在招募
    A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
    分期
    III期
    开始
    2022-01
    发布
    登记号
    NCT05851014

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、临沂、佛山、南京、南宁、南昌、合肥、宁波、广州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、银川、长春、长沙

  24. 正在招募
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    分期
    IV期
    开始
    2021-06
    发布
    登记号
    NCT04790305

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院;另有 26 家列出的医院为研究中心上海、北京、南京、合肥、宁波、广州、扬州、武汉、沈阳、济南、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  25. 正在招募
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
    分期
    II期
    开始
    2020-09
    发布
    登记号
    NCT04557449

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、杭州、武汉、西安、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科放疗科病理/检验科影像/核医学科
牵头的论文45
  1. Study on Different Staining Platforms for HER2 Cytoplasmic Granular Staining Pattern in Pure Apocrine Carcinoma of the Breast.2026Clinical breast cancer
  2. Development of an Ultrasound-Based Radiomics Nomogram for Preoperative Prediction of HER-2 Status in Invasive Breast Cancer.2025Academic radiology
  3. Intraductal chemotherapy for triple-negative breast cancer: a pathway to minimally invasive clinical treatment.2025BMC cancer免费全文
  4. Neoadjuvant stereotactic body radiotherapy combined with chemotherapy and Ivonescimab for Chinese luminal-type breast cancer patients: study protocol for a single-arm, open-label, phase II trial.2025BMJ open免费全文
  5. Salvianic acid A enhances anti-PD-1 therapy by promoting HEV-mediated stem-like CD8 T cells infiltration in TNBC.2025Cancer immunology, immunotherapy : CII免费全文
  6. The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients.2025Cancer letters
  7. The Critical Role of Inhibitor of Differentiation 4 in Breast Cancer: From Mammary Gland Development to Tumor Progression.2025Cancer medicine免费全文
  8. Comparison of Random Survival Forest Based-Overall Survival With Deep Learning and Cox Proportional Hazard Models in HER-2-Positive HR-Negative Breast Cancer.2025Cancer reports (Hoboken, N.J.)免费全文
  9. Construction of a Nomogram Model for Predicting Pathologic Complete Response in Breast Cancer Neoadjuvant Chemotherapy Based on the Pan-Immune Inflammation Value.2025Current oncology (Toronto, Ont.)免费全文
  10. Glabridin from Glycyrrhiza glabra L. Exhibits Anti-Triple-Negative Breast Cancer Effects by Regulating Various Cell Cycle Genes.2025Journal of agricultural and food chemistry
  11. Patient-reported outcomes following various incision techniques in breast reconstruction: an observational cohort study in China.2025Journal of cancer research and clinical oncology免费全文
  12. Human epidermal growth factor receptor 2 and androgen receptor expression in invasive breast carcinoma of no special type with medullary pattern.2025Journal of cancer research and therapeutics
  13. Single-Cell Transcriptome Analysis Uncovers La Ribonucleoprotein 6 (LARP6) as a Dual Regulator of Proliferation and Immune Infiltration in Triple-Negative Breast Cancer.2025Journal of cellular and molecular medicine免费全文
  14. Detection of Circulating Tumor Cells in the Prognostic Significance of Patients With Breast Cancer: A Retrospective Study.2025Journal of clinical laboratory analysis免费全文
  15. Advances in novel cell death mechanisms in breast cancer: intersecting perspectives on ferroptosis, cuproptosis, disulfidptosis, and pyroptosis.2025Molecular cancer免费全文
  16. HMGB3 Contributes to Anti-PD-1 Resistance by Inhibiting IFN-γ-Driven Ferroptosis in TNBC.2025Molecular carcinogenesis
  17. Ensemble model for neoadjuvant chemotherapy response prediction and treatment sensitivity in TNBC based on DNA replication stress signatures.2025Scientific reports免费全文
  18. Comparison of nipple sparing and skin sparing mastectomy with immediate reconstruction based on patient reported outcomes.2025Scientific reports免费全文
  19. Efficacy and safety of oncoplastic breast-conserving surgery versus conventional breast-conserving surgery: An updated meta-analysis.2024Breast (Edinburgh, Scotland)免费全文
  20. Lung toxicity induced by anti-HER2 antibody - drug conjugates for breast cancer.2024Critical reviews in oncology/hematology
  21. ALG3 predicts poor prognosis and increases resistance to anti-PD-1 therapy through modulating PD-L1 N-link glycosylation in TNBC.2024International immunopharmacology
  22. Association of explicit and implicit social support with psychological adjustment in Chinese women with breast cancer: An interpersonal explanation.2024Journal of health psychology
  23. Effects of Degreasing Pretreatment on Immunohistochemistry and Molecular Analysis of Gastrointestinal and Breast Cancer Samples.2024Laboratory investigation; a journal of technical methods and pathology
  24. Whole-brain radiation therapy plus simultaneous integrated boost for brain metastases from breast cancers.2024PeerJ免费全文
  25. Giant low-grade myofibroblastic sarcoma of the male breast: case report and literature review.2024Polish journal of pathology : official journal of the Polish Society of Pathologists
  26. Overexpression of SLAP2 inhibits triple-negative breast cancer progression by promoting macrophage M1-type polarization.2024Scientific reports免费全文
  27. Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway.2024Scientific reports免费全文
  28. Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer.2024Signal transduction and targeted therapy免费全文
  29. DEPDC1B-mediated USP5 deubiquitination of β-catenin promotes breast cancer metastasis by activating the wnt/β-catenin pathway.2023American journal of physiology. Cell physiology免费全文
  30. Cuproptosis and cuproptosis-related genes: Emerging potential therapeutic targets in breast cancer.2023Biochimica et biophysica acta. Reviews on cancer
  31. Excellent response of refractory triple-negative breast cancer to sintilimab plus chemotherapy: a case report.2023Immunotherapy
  32. LncRNA MIR17HG Suppresses Breast Cancer Proliferation and Migration as ceRNA to Target FAM135A by Sponging miR-454-3p.2023Molecular biotechnology免费全文
  33. A tumor cell exosome-mimicking multifunctional nanozyme for targeted breast cancer radiotherapy.2023Nanoscale
  34. Correlation between dynamic contrast-enhanced MRI characteristics and apparent diffusion coefficient with Ki-67-positive expression in non-mass enhancement of breast cancer.2023Scientific reports免费全文
  35. Survival Comparisons between Breast Conservation Surgery and Mastectomy Followed by Postoperative Radiotherapy in Stage I-III Breast Cancer Patients: Analysis of the Surveillance, Epidemiology, and End Results (Seer) Program Database.2022Current oncology (Toronto, Ont.)免费全文
  36. Analysis of risk factors related to acute radiation dermatitis in breast cancer patients during radiotherapy.2022Journal of cancer research and therapeutics
  37. HIF‑1α and MBP1 are associated with the progression of breast cancer cells by repressing β‑catenin transcription.2022Oncology reports免费全文
  38. Partial Latissimus Dorsi Muscle Flap With Implant for Immediate Breast Reconstruction.2022The Journal of surgical research
  39. LncRNA-HAGLR motivates triple negative breast cancer progression by regulation of WNT2 via sponging miR-335-3p.2021Aging免费全文
  40. N6-Methyladenosine-regulated LINC00675 suppress the proliferation, migration and invasion of breast cancer cells via inhibiting miR-513b-5p.2021Bioengineered免费全文
  41. CircRASSF2 acts as a prognostic factor and promotes breast cancer progression by modulating miR-1205/HOXA1 axis.2021Bioengineered免费全文
  42. Distinct Clinical Impact and Biological Function of Angiopoietin and Angiopoietin-like Proteins in Human Breast Cancer.2021Cells免费全文
  43. MAGI2-AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2.2021Journal of cellular physiology
  44. MMP11 promotes the proliferation and progression of breast cancer through stabilizing Smad2 protein.2021Oncology reports免费全文
  45. Factors associated with psychological distress among patients with breast cancer during the COVID-19 pandemic: a cross-sectional study in Wuhan, China.2021Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer免费全文
中文论文(未计入)1
  1. [Improved method to prevent false-negative immunohistochemical detection by Ventana platform with hydrophobic tablets].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)72
  1. Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib正在招募NCT07264985牵头方2025-12 启动
  2. A Study on Combined Low-pass Whole-genome and Methylome Testing of Bloody Nipple Discharge Specimens for Benign-Malignant Differentiation.正在招募NCT07250204牵头方2025-12 启动
  3. DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes正在招募NCT07263347牵头方2025-12 启动
  4. Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea正在招募NCT07264998牵头方2025-12 启动
  5. SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)正在招募NCT06401005牵头方II期2024-11 启动
  6. SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer正在招募NCT06402435牵头方II期2024-11 启动
  7. Investigating the Effects of Different Incision Types on Aesthetic Outcomes and Incision-related Complications After Breast Reconstruction Surgery邀请入组NCT06258863牵头方2023-07 启动
  8. Neoadjuvant Radiotherapy and Immediate Implant-Based Breast Reconstruction状态不明NCT05992870牵头方不分期2023-07 启动
  9. A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer正在招募NCT07347600研究中心2026-01 启动
  10. Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer正在招募NCT06993506研究中心2026-05 启动
  11. A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)正在招募NCT07876557研究中心II期2026-10 启动
  12. Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain正在招募NCT07490938研究中心不分期2026-04 启动
  13. RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive正在招募NCT07413939研究中心II/III期2026-05 启动
  14. BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease正在招募NCT07492641研究中心III期2026-05 启动
  15. JS207 Combination Therapy in Triple-negative Breast Cancer正在招募NCT07045311研究中心II期2025-09 启动
  16. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.正在招募NCT07062965研究中心III期2025-08 启动
  17. A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer正在招募NCT07673029研究中心III期2025-01 启动
  18. A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)正在招募NCT06926868研究中心II/III期2025-09 启动
  19. A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.正在招募NCT06064812研究中心I/II期2023-09 启动
  20. A Study of YL202 in Selected Patients With Advanced Solid Tumors正在招募NCT06107686研究中心II期2023-12 启动
  21. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation正在招募NCT05696626研究中心III期2023-10 启动
  22. A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy正在招募NCT05646862研究中心III期2023-06 启动
  23. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer正在招募NCT05894239研究中心III期2023-09 启动
  24. A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer正在招募NCT05851014研究中心III期2022-01 启动
  25. Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer正在招募NCT04790305研究中心IV期2021-06 启动
  26. Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors正在招募NCT04557449研究中心II期2020-09 启动
  27. Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease进行中,不再招募NCT06760637研究中心III期2025-01 启动
  28. Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors进行中,不再招募NCT06380660研究中心I/II期2024-03 启动
  29. A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer进行中,不再招募NCT06561607研究中心III期2024-10 启动
  30. A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)进行中,不再招募NCT06680921研究中心III期2024-11 启动
  31. PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC进行中,不再招募NCT06419621研究中心III期2024-06 启动
  32. A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer已完成NCT05945927研究中心2023-09 启动
  33. A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer进行中,不再招募NCT05654623研究中心III期2023-03 启动
  34. Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy进行中,不再招募NCT05840211研究中心III期2023-05 启动
  35. A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)进行中,不再招募NCT06065748研究中心III期2023-12 启动
  36. Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer进行中,不再招募NCT05909397研究中心III期2023-08 启动
  37. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903已完成NCT06846099研究中心I期2022-12 启动
  38. Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies进行中,不再招募NCT05226871研究中心II期2022-07 启动
  39. A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors进行中,不再招募NCT05339685研究中心I期2022-05 启动
  40. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer进行中,不再招募NCT05346224研究中心III期2022-04 启动
  41. Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer进行中,不再招募NCT05382299研究中心III期2022-07 启动
  42. A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer进行中,不再招募NCT05514054研究中心III期2022-10 启动
  43. A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer进行中,不再招募NCT05132582研究中心III期2022-03 启动
  44. A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer状态不明NCT05433480研究中心III期2022-05 启动
  45. Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer进行中,不再招募NCT04851613研究中心III期2022-02 启动
  46. A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)进行中,不再招募NCT04961996研究中心III期2021-08 启动
  47. GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer已完成NCT05054751研究中心III期2021-09 启动
  48. A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer已终止NCT04927481研究中心II期2021-06 启动
  49. A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer已终止NCT04752332研究中心III期2021-05 启动
  50. A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer进行中,不再招募NCT04975308研究中心III期2021-10 启动
  51. Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors状态不明NCT05145907研究中心II期2021-12 启动
  52. Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .状态不明NCT04234620研究中心2020-02 启动
  53. Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)进行中,不再招募NCT04639986研究中心III期2020-11 启动
  54. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  55. A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer已完成NCT04024462研究中心III期2020-02 启动
  56. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment已终止NCT04178460研究中心I期2020-02 启动
  57. A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer进行中,不再招募NCT04191499研究中心II/III期2020-01 启动
  58. A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)进行中,不再招募NCT04576455研究中心II期2020-11 启动
  59. Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors状态不明NCT04450732研究中心I期2020-07 启动
  60. Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments进行中,不再招募NCT04454437研究中心II期2020-10 启动
  61. A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer进行中,不再招募NCT03975647研究中心III期2019-10 启动
  62. Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC进行中,不再招募NCT03562637研究中心III期2018-12 启动
  63. The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer状态不明NCT04185649研究中心III期2018-07 启动
  64. A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases状态不明NCT03500380研究中心II/III期2018-04 启动
  65. Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)进行中,不再招募NCT03725059研究中心III期2018-12 启动
  66. A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer已终止NCT03498716研究中心III期2018-08 启动
  67. Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment已完成NCT04085276研究中心III期2018-12 启动
  68. Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]已完成NCT03734029研究中心III期2018-12 启动
  69. Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer已完成NCT03084237研究中心III期2016-11 启动
  70. A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer进行中,不再招募NCT02763566研究中心III期2016-12 启动
  71. A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]已完成NCT02297438研究中心III期2015-03 启动
  72. A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer已完成NCT01358877研究中心III期2011-11 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.04%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

武汉有 22 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

武汉有 9 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    发布
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 10 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

淋巴瘤

Lymphoma

2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.08%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

武汉有 4 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下

这家医院参与的开放试验 7

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
    分期
    III期
    开始
    2026-03
    发布
    登记号
    NCT07409428

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 42 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、合肥、哈尔滨、天津、太原、广州、徐州、成都、杭州、武汉、沈阳、泉州、济南、福州、蚌埠、西安、贵阳、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
    分期
    III期
    开始
    2025-01
    发布
    登记号
    NCT06717347

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、北京、南宁、南昌、南通、厦门、合肥、天津、太原、广州、成都、武汉、济南、福州、贵阳、重庆、长春

  3. 正在招募
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
    分期
    I/II期
    开始
    2025-04
    发布
    登记号
    NCT06829771

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、兰州、北京、哈尔滨、天津、太原、广州、徐州、武汉、泉州、泸州、烟台、福州、蚌埠、西安、郑州、长春

  4. 正在招募
    Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
    分期
    II期
    开始
    2025-03
    发布
    登记号
    NCT06854445

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 21 家列出的医院为研究中心兰州、南京、南宁、南昌、厦门、哈尔滨、大连、太原、杭州、武汉、泸州、济南、石家庄、芜湖、苏州、西安、郑州、长沙

  5. 正在招募
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
    分期
    II期
    开始
    2025-11
    发布
    登记号
    NCT07189065

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、合肥、大连、天津、太原、广州、徐州、成都、杭州、武汉、沈阳、洛阳、石家庄、福州、苏州、郑州、重庆、长春、长沙

  6. 正在招募
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT07234162

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、临沂、兰州、北京、南京、南宁、厦门、合肥、哈尔滨、天津、太原、广州、成都、杭州、武汉、沈阳、济南、温州、福州、西安、郑州、重庆、长春、长沙

  7. 即将招募
    Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
    分期
    III期
    开始
    2025-11
    发布
    登记号
    NCT07187960

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、兰州、北京、南京、南昌、天津、太原、武汉、沈阳、海口、烟台、西安、贵阳、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科病理/检验科
牵头的论文3
  1. Suicide among lymphoma patients.2024Journal of affective disorders
  2. Composite ALK-negative anaplastic large cell lymphoma and follicular lymphoma involving jejunum and mesenteric lymph nodes.2024Pathology international
  3. Involvement of spleen is associated with shorter survival in patients with angioimmunoblastic T cell lymphoma.2023Journal of cancer research and clinical oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)25
  1. Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL状态不明NCT06224842牵头方(推断)I/II期2023-12 启动
  2. A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL正在招募NCT07409428研究中心III期2026-03 启动
  3. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)正在招募NCT06717347研究中心III期2025-01 启动
  4. A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma正在招募NCT07189065研究中心II期2025-11 启动
  5. Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma即将招募NCT07187960研究中心III期2025-11 启动
  6. Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma正在招募NCT06829771研究中心I/II期2025-04 启动
  7. Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma正在招募NCT06854445研究中心II期2025-03 启动
  8. A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)正在招募NCT07234162研究中心III期2024-05 启动
  9. Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma进行中,不再招募NCT06191744研究中心III期2024-02 启动
  10. A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma进行中,不再招募NCT06508658研究中心III期2024-08 启动
  11. A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma进行中,不再招募NCT05716087研究中心II期2023-02 启动
  12. A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)进行中,不再招募NCT05578976研究中心III期2023-02 启动
  13. Evaluating Different Doses of Orelabrutinib in MCL已完成NCT05978739研究中心II期2023-08 启动
  14. A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma已终止NCT05354362研究中心I期2022-03 启动
  15. A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China进行中,不再招募NCT07226752研究中心III期2022-10 启动
  16. Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma状态不明NCT05422066研究中心II期2022-07 启动
  17. Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma进行中,不再招募NCT05409066研究中心III期2022-09 启动
  18. Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma状态不明NCT05381506研究中心II期2022-07 启动
  19. AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)已完成NCT06511869研究中心II期2022-03 启动
  20. A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas已暂停NCT05279300研究中心I期2022-03 启动
  21. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma已完成NCT03992339研究中心II期2020-04 启动
  22. A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma已终止NCT04425070研究中心I/II期2020-08 启动
  23. Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab已完成NCT04282018研究中心I/II期2020-04 启动
  24. Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma已完成NCT03934814研究中心I期2019-04 启动
  25. A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection已完成NCT04569838研究中心II期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

湖北省肿瘤医院

Hubei Cancer Hospital

武汉

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Hubei Cancer Clinical Study Center; and Hubei Cancer Clinical Study Center; Hubei Cancer Clinical Study Centre; HuBei Cancer Hospital; HBCH

提出更正下载数据